GRAND PHARMA(00512),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00512 GRAND PHARMA

Market Closed 04-02 16:08:21

7.220

+0.070

+0.98%

High7.240	Low7.090	Vol7.73M
Open7.150	D1 Closing7.150	Amplitude2.10%
Mkt Cap25.63B	Tradable Cap25.63B	Total Shares3.55B
T/O55.43M	T/O Rate0.22%	Tradable Shares3.55B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"GRAND PHARMA","latestPrice":7.22,"timestamp":1775117301002,"preClose":7.15,"halted":0,"volume":7731000,"delay":0,"changeRate":0.009790209790209706,"floatShares":3549571148,"shares":3550000000,"eps":0.3544,"marketStatus":"Market Closed","change":0.07,"latestTime":"04-02 16:08:21","open":7.15,"high":7.24,"low":7.09,"amount":55429240,"amplitude":0.020979,"askPrice":7.22,"askSize":23000,"bidPrice":7.21,"bidSize":14500,"shortable":3,"etf":0,"ttmEps":0.3544,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":819302400000,"exchange":"SEHK","adjPreClose":7.15,"dividendRate":0.035997,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.9918473508952728,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512/tweets","defaultTab":"tweets","newsList":[{"id":"2624666777","title":"Why Grand Pharmaceutical Group (SEHK:512) Is Up 9.7% After Mixed 2025 Results And New Drug Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2624666777","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624666777?lang=en_us&edition=fundamental","pubTime":"2026-04-03 21:23","pubTimestamp":1775222627,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical Group reported its 2025 results with sales rising to HK$12,283.27 million while net income and EPS fell sharply, and it announced a lower annual dividend alongside guidance citing investment fair value losses and pressure from centralized drug procurement.\nAt the same time, the group advanced its innovation pipeline with Chinese approval to commercialize GPN01768 for Demodex blepharitis and Phase II clearance for migraine candidate GPN01020, underlining a push to offset...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/why-grand-pharmaceutical-group-sehk512-is-up-97-after-mixed","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/why-grand-pharmaceutical-group-sehk512-is-up-97-after-mixed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AIPO","00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167530541","title":"Stock Track | Grand Pharma Soars 5.01% Intraday on Chairman's Share Purchase Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=1167530541","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167530541?lang=en_us&edition=fundamental","pubTime":"2026-03-30 09:34","pubTimestamp":1774834494,"startTime":"0","endTime":"0","summary":"Grand Pharma's stock price surged 5.01% during intraday trading on Monday, reflecting strong positive momentum.The sharp rise appears to be driven by news that the company's Board Chairman, Tang...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191291904","title":"Board Chairman of Grand Pharma Purchases 60,000 Shares at HK$6.5 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1191291904","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191291904?lang=en_us&edition=fundamental","pubTime":"2026-03-30 08:20","pubTimestamp":1774830042,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on March 27, Board Chairman Tang Weikun acquired 60,000 shares of Grand Pharma (00512) at a price of HK$6.5 per share, totaling...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623353504","title":"A Look At Grand Pharmaceutical Group (SEHK:512) Valuation After 2025 Earnings Reset And New Ophthalmic Drug Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2623353504","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623353504?lang=en_us&edition=fundamental","pubTime":"2026-03-29 17:09","pubTimestamp":1774775368,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical Group (SEHK:512) has just posted its full year 2025 results, reporting higher sales, sharply lower net income, a reduced annual dividend, and fresh NMPA approval for ophthalmic drug GPN01768.\nSee our latest analysis for Grand Pharmaceutical Group.\nThe share price is HK$6.78 after a 3.04% 1 day share price return. The 30 day share price return of 12.52% and year to date share price return of 13.08% point to fading short term momentum despite a 3 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/a-look-at-grand-pharmaceutical-group-sehk512-valuation-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/a-look-at-grand-pharmaceutical-group-sehk512-valuation-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188909938","title":"Chairman Tang Weikun Increases Stake in GRAND PHARMA with 60,000 Shares at HK$6.5 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1188909938","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188909938?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:51","pubTimestamp":1774612279,"startTime":"0","endTime":"0","summary":"On March 27, Chairman Tang Weikun purchased 60,000 shares of GRAND PHARMA (00512) at a price of HK$6.5 per share, totaling HK$390,000. Following this transaction, his total shareholding has risen to 1.06 million shares, representing 0.03% of the company's equity.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198313473","title":"Nuclear Medicine Leadership and Innovation Breakthroughs: GRAND PHARMA (00512) Accelerates Value Realization in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1198313473","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198313473?lang=en_us&edition=fundamental","pubTime":"2026-03-27 08:54","pubTimestamp":1774572852,"startTime":"0","endTime":"0","summary":"Since the beginning of 2026, the Hong Kong stock market's healthcare sector has experienced continuous volatility due to multiple external factors. Unlike the 2025 biotech bull market, which was...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622864864","title":"BRIEF-Grand Pharmaceutical Group Posts FY Revenue HKD 12,283.27 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622864864","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622864864?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:24","pubTimestamp":1774538696,"startTime":"0","endTime":"0","summary":"BRIEF-Grand Pharmaceutical Group Posts FY Revenue HKD 12,283.27 MillionMarch 26  - Grand Pharmaceutical Group Ltd 0512.HK:FY REVENUE HKD 12,283.27 MILLIONFINAL DIVIDEND HK$0.169 PER SHAREFY NET INCOME ATTRIBUTABLE HKD 1,240.9 MILLIONFurther company coverage: 0512.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLX2C66D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129240899","title":"Grand Pharma Declares HKD 0.169 Final Dividend for FY 2025; Payment Slated for 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1129240899","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129240899?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:05","pubTimestamp":1774537551,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical Group Limited (Grand Pharma) has announced a final ordinary dividend of HKD 0.169 per share for the financial year ended 31 December 2025, according to its filing with the Stock...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120612679","title":"GRAND PHARMA Reports Record High Contribution from Innovative Products; Nuclear Medicine Segment Revenue Surges Nearly 15-Fold in Four Years","url":"https://stock-news.laohu8.com/highlight/detail?id=1120612679","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120612679?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:05","pubTimestamp":1774537529,"startTime":"0","endTime":"0","summary":"GRAND PHARMA (00512) announced its 2025 financial results on March 26. The company recorded annual revenue of approximately HKD 12.28 billion, representing a year-on-year increase of about 14.8%...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155852614","title":"Robust Resilience Across Cycles Unleashes Long-Term Value, Grand Pharma (00512) Achieves HKD 12.28 Billion Revenue in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1155852614","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155852614?lang=en_us&edition=fundamental","pubTime":"2026-03-26 22:54","pubTimestamp":1774536887,"startTime":"0","endTime":"0","summary":"Grand Pharma (00512) disclosed its 2025 financial report on March 26. The company reported annual revenue of approximately HKD 12.28 billion, representing a year-on-year increase of about 14.8% after...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622022682","title":"BRIEF-Grand Pharmaceutical Group Says NMPA Approves GPN01020 For Phase II Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2622022682","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622022682?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:25","pubTimestamp":1774434301,"startTime":"0","endTime":"0","summary":"BRIEF-Grand Pharmaceutical Group Says NMPA Approves GPN01020 For Phase II Clinical TrialMarch 25 (Reuters) - Grand Pharmaceutical Group Ltd 0512.HK:NMPA APPROVES GPN01020 FOR PHASE II CLINICAL TRIAL FOR MIGRAINE PREVENTIONFurther company coverage: 0512.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129200452","title":"Grand Pharma's Traditional Chinese Medicine Innovative Drug GPN01020 Approved for Phase II Clinical Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1129200452","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129200452?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:16","pubTimestamp":1774433792,"startTime":"0","endTime":"0","summary":"Grand Pharma (00512) announced that its innovative Traditional Chinese Medicine drug GPN01020, intended for the preventive treatment of migraines, has recently received approval from the National...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01020","06978","BK1191","159992","00512","BK1094","BK1142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622024942","title":"Grand Pharmaceutical’s GPN01020 wins NMPA clearance for China Phase II migraine trial; study targets 180 patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024942","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024942?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:01","pubTimestamp":1774432902,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical said China’s National Medical Products Administration approved its Class 1.1 innovative traditional Chinese medicine GPN01020 to conduct a Phase II clinical trial in China for the preventive treatment of migraines.The randomized, double-blind, placebo-controlled, multicenter Phase II study plans to enroll 180 patients with migraine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL40hNmT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622002496","title":"Grand Pharmaceutical Group Ltd - Nmpa Approves Gpn01020 for Phase Ii Clinical Trial for Migraine Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2622002496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622002496?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:01","pubTimestamp":1774432872,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102803258","title":"GRAND PHARMA's Partner Telix Reports Positive Phase III Progress for First-in-Class Prostate Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1102803258","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102803258?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:06","pubTimestamp":1774350390,"startTime":"0","endTime":"0","summary":"GRAND PHARMA's strategic partner in the nuclear medicine field, Australian company Telix, has announced significant positive news. The first part of the international multi-center Phase III clinical...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0238","BK0012","III","00512","BK0187","BK4134","BK0188","BK0196","000876","BK1191","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621094997","title":"BUZZ-Tarsus rises as China approval unlocks $15 million milestone for eye drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2621094997","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621094997?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:36","pubTimestamp":1774272994,"startTime":"0","endTime":"0","summary":"BUZZ-Tarsus rises as China approval unlocks $15 million milestone for eye drug** Shares of drugmaker Tarsus Pharmaceuticals TARS.O rise 3.5% to $62.25** Co says it will receive $15 mln milestone payment, after partner Grand Pharmaceutical Group wins Chinese approval for eye drug TP-03** The drug, sold as Xdemvy in U.S., is approved in China to treat Demodex blepharitis, an eyelid condition caused by tiny mites that leads to itching and irritation** Co says the drug is the first approved treatment for the disease in China** Grand Pharma holds exclusive rights to develop and sell the drug in Greater China, including mainland China, Hong Kong, Macau and Taiwan** Tarsus says over 40 mln people in the region are affected; co is also eligible for further regulatory and sales milestones and future royalties** Shares up ~49% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL4N40B13J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","00512","BK1191","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621053727","title":"Tarsus TP-03 wins China NMPA approval, triggering USD 15 million milestone payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2621053727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621053727?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:30","pubTimestamp":1774269035,"startTime":"0","endTime":"0","summary":"China’s NMPA approved TP-03  0.25% for Demodex blepharitis in the Greater China region.Grand Pharma obtained the approval and will develop and commercialize TP-03 in the region under its partnership with Tarsus.The approval triggered a USD 15 million milestone payment to Tarsus.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLhz8F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","IE00BN0W2W23.USD","BK4112","00512","LU2095319765.USD","LU0314104364.USD","BK4585","IE00BN0W2V16.EUR","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4007","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115702498","title":"Groundbreaking Nasal Spray from GRAND PHARMA Offers Relief for 250 Million Allergy Sufferers","url":"https://stock-news.laohu8.com/highlight/detail?id=1115702498","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115702498?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:05","pubTimestamp":1774263926,"startTime":"0","endTime":"0","summary":"As the warm winter effect continues into the spring of 2026, pollen seasons have started significantly earlier across many parts of the country, heralding a new wave of symptom peaks for China's 250...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621721797","title":"Grand Pharmaceutical Group Forecasts Lower Profit For 2025; TP-03 Approved in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2621721797","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621721797?lang=en_us&edition=fundamental","pubTime":"2026-03-23 13:16","pubTimestamp":1774242989,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical Group  said it expects HK$1.20 billion to HK$1.25 billion in attributable profit for 2025, falling from HK$2.47 billion in 2024, according to a Hong Kong bourse filing Friday.Shares of the pharmaceutical company fell nearly 8% in late morning trade Monday.The firm attributed the decrease to a number of factors, including a rise in marketing and promotion-related expenses during the year.The company expects to generate HK$12 billion to HK$12.5 billion in revenue for the year, compared with HK$11.64 billion in 2024.The company's financial results are due March 26.Meanwhile, in a separate announcement, the firm said its TP-03 product was approved for commercialization in China.The medicine is meant to treat an eyelid inflammation condition known as demodex blepharitis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110525857","title":"Grand Pharma obtains NMPA clearance for TP-03, China’s first approved therapy for Demodex blepharitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1110525857","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110525857?lang=en_us&edition=fundamental","pubTime":"2026-03-22 18:21","pubTimestamp":1774174882,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical Group Limited (Grand Pharma) announced that the National Medical Products Administration (NMPA) has granted a Drug Registration Certificate for GPN01768 [TP-03, lotilaner...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":0.0973},{"period":"1month","weight":-0.0082},{"period":"3month","weight":-0.0744},{"period":"6month","weight":-0.1526},{"period":"1year","weight":0.2025},{"period":"ytd","weight":-0.0803}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialised pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":0.084101},{"month":2,"riseRate":0.709677,"avgChangeRate":0.105021},{"month":3,"riseRate":0.387097,"avgChangeRate":0.015578},{"month":4,"riseRate":0.645161,"avgChangeRate":0.018568},{"month":5,"riseRate":0.466667,"avgChangeRate":0.084333},{"month":6,"riseRate":0.366667,"avgChangeRate":-0.048262},{"month":7,"riseRate":0.366667,"avgChangeRate":-0.015905},{"month":8,"riseRate":0.4,"avgChangeRate":0.007133},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.039275},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014834},{"month":11,"riseRate":0.5,"avgChangeRate":0.085694},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007596}],"exchange":"SEHK","name":"GRAND PHARMA","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRAND PHARMA(00512),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GRAND PHARMA(00512) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GRAND PHARMA,00512,GRAND PHARMA股票,GRAND PHARMA股票老虎,GRAND PHARMA股票老虎国际,GRAND PHARMA行情,GRAND PHARMA股票行情,GRAND PHARMA股价,GRAND PHARMA股市,GRAND PHARMA股票价格,GRAND PHARMA股票交易,GRAND PHARMA股票购买,GRAND PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRAND PHARMA(00512),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GRAND PHARMA(00512) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}